Stocks and Investing Stocks and Investing
Mon, July 16, 2018
Fri, July 13, 2018

Matthew Harrison Maintained (BIIB) at Buy with Decreased Target to $366 on, Jul 13th, 2018


Published on 2024-10-26 06:46:27 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $369 to $366 on, Jul 13th, 2018.

Matthew has made no other calls on BIIB in the last 4 months.



There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Skorney of "Baird" Downgraded from Buy to Hold on, Tuesday, July 10th, 2018
  • Geoff Meacham of "Barclays" Downgraded from Buy to Hold on, Thursday, April 5th, 2018


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Robyn Karnauskas of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $371 on, Friday, July 6th, 2018
  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy on, Thursday, May 31st, 2018
Contributing Sources